Sigma Receptors and Sigma Ligands: Background to a Pharmacological Enigma

Although it is now well established that the sigma receptors are distinct from neurotransmitter, neuropeptide and steroid receptors, their precise physiological role, and possible involvement in the pathology of neurological and psychiatric disorders, remains an enigma. The purpose of this short review is to provide a basis upon which to explain the pharmacological properties of such a diverse group of drugs as the antidepressants, antipsychotics and neuroprotective agents. However, a greater understanding of the importance of the sigma receptors will depend on the development of more potent and selective sigma agonists and antagonists if the therapeutic potential of the sigma receptors is to be fully realised.

Key words

sigma-1 - sigma-2 receptors - endogenous ligands - antidepressants - antipsychotics - SSRI’s - dystonia

References

• 1 Bergeron R, DeBonnel G, de Montigny C. Modification of the NMDA response by antidepressant sigma receptor ligands.  Eur J Pharmacol. 1993;  240 319-323
• 2 Bergeron R, de Montigny C, DeBonnel G. Bipohasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate.  Naunyn-Schmiedeberg’s Arch Pharmacol. 1996;  351 252-260
• 3 Bowen W D, Tolentino P, Varghese P. Investigation of the mechanism by which sigma ligands inhibit stimulation of phosphoinositide metabolism by muscarinic cholinergic agonists.  Prog Clin Biol Res. 1989;  328 21-24
• 4 Clay G A, Brougham L R. Haloperidol binding to an opiate receptor site.  Biochem Pharmacol. 1975;  24 1363-1367
• 5 Conner M A, Chavkin C. Ionic zinc may function as an endogenous ligand for haloperidol sensitive sigma-2 receptor in rat brain.  Mool Pharmacol. 1992;  42 471-479
• 6 Contreras P C, Di Maggio D A, O’Donohue T L. An endogenous ligand for the sigma opioid binding site.  Synapse. 1987;  1 57-61
• 7 Deutsch S L, Weizman A, Goldman M E, Morihisa J M. The sigma-receptor:a novel site implicated in psychosis and antipsychotic drug efficacy.  Clin Neuropharmacol. 1988;  11 105-119
• 8 Faherty C J, Harkin A J, Leonard B E. The functional modulation of sigma receptors following chronic SSRI treatment. Eur J Pharmacol 1997
• 9 Gray N M, Contreras P C, Allen S E, Taylor D P. H1 antihistamines interact with central sigma receptors.  Life Sci. 1990;  47 175-180
• 10 Harris L S, Pierson A K. Some narcotic antagonistsin the benzomerphan series.  J Pharmacol Exp Ther . 1964;  143 141-148
• 11 Itzhak Y, Kassim C O. Clorgyline displays high affinity for sigma sites in C57-BL/6 mouse brain.  Eur J Pharmacol. 1990;  176 107-108
• 12 Itzhak Y, Mash D, Zhang S H, Stin I. Characterization of MPTP binding sites in C57 BL/6 mouse brain;mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites.  Mol Pharmacol. 1991;  39 385-393
• 13 Ivory J D. The effects of putative antipsychotic drugs and antidepressants on sigma receptors in the rat brain M.Sc thesis. National University of Ireland Galway; 1994
• 14 Junien J -L, Gue M, Bbueno L. Neuropeptide-Y and sigma ligand Jo 1784 act through a Gi protein to block the psychological stress and CRF induced colonic motor activation in rats.  Neuropharmacol. 1991;  30 119-124
• 15 Klein M, Carroll P D, Musacchio J M. SKF-525A and cytochrome P450 ligands inhibit with high affinity the binding of 3H-dextromethorphan and ligands to guinea pig brain.  Life Sci. 1991;  48 543-550
• 16 Konig F, von Hippel C, Petersdorff T, Neuhoffer-Weiss M, Wolfersdorf M, Kaschka W P. First experiences in combination therapy using olanzapine with SSRI’s (citalopram, paroxetine) in delusional depression.  Neuropsychobiol. 2001;  43 170-174
• 17 Lammers C H, Deuschle M, Weigmann H, Hartter S, Hiemke C, Hesse C, Heuser I. Coadministration of clozapine and fluvoxamine in psychotic patients-clinical experience.  Pharmacopsychiat. 1999;  32 76-77
• 18 Largent B L, Wikstrom H, Gunlach A L, Snyder S H. Structural determinants of sigma receptor affinity.  Mol Pharmacol. 1987;  32 772-784
• 19 Lasagna L, Beecher H K. The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man.  J Pharmacol Exp Ther. 1954;  112 356-363
• 20 Leonard B E, Faherty C J. SSRI’s and movement disorders: is serotonin the culprit?.  Hum Psychopharmacol. 1996;  11(suppl.2) S 75-82
• 21 Leonard B E, Nicholson C D. Ssigma ligands ars potential psychotropic drugs.  J Psychopharmacol. 1994;  8 64-65
• 22 McCann D J, Weissman A D, Su J- P. Sigma-1 and sigma-2 sites in rat brain: comparison of regional ontogenetic and subcellular patterns.  Synapse. 1994;  17 182-189
• 23 Magnan J, Patterson S J, Tavani A, Zosterlitz H W. The binding spectrum of narcotic analgesics with different agonists and antagonist properties.  Nauyn-Schmiedeberg’s Arch Pharmacol. 1982;  319 197-319
• 24 Martin W R, Eades C G, Thompson W O, Huppler R E, Glibert P E. The effect of morphine and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog.  J Pharmacol Exp Ther. 1976;  197 517-532
• 25 Matsumoto R R, Walker J M. Iontophoretic effects of putative sigma ligands on rubral neurons in the rat Brain Res.  Bull. 1992;  29 419-425
• 26 Monnet F P, DeBonnel G, de Montigny C. Neuropeptide-Y selectively potentiates NMDA induced neuronal activation.  Eur J Phharmacol. 1990;  182 207-208
• 27 Monnet F P, Mahe V, Robel P, Beulien E D. Neurosteroids, via sigma receptors, modulate the 3H-noradrenaline release evoked by N-methyl-D-aspartate in the rathippocampus.  Proc Natl Acad Sci USA. 1995;  92 3774-3778
• 28 Narita N, Hashimoto K, Tomitaki S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sugma receptor in rat brain.  Eur J Pharmacol. 1996;  307 117-119
• 29 Paul I A, Nowak G, Layer R T, Popik P, Skolnick P. Adaptation of ther NMDA receptor complex following chronic antidepressant treatments.  J Pharmacol Exp Ther. 1994;  269 95-102
• 30 Quirion R, Chicheportiche R, Contreras P C, Johnson K M, Lodge D. Classification and nomenclature of phencyclidine and sigma receptor sites.  TINS. 1987;  10 444-446
• 31 Quirion R, Bowen W D, Itzhak Y, Junien J- L, Musacchio R B. A proposal for the classification of sigma binding sites.  TIPS. 1992;  13 85-87
• 32 Reddy D S, Kaur G, Kulkarni S K. Sigma-1 receptor mediated anti-depressant -like effects of neurosteroids in the Porsolt forced swim test.  Neuroreport. 1989;  9 3069-3073
• 33 Redrobe J P, Carvajal C, Kask A, Dumont Y, Quirion R. Neuropeptide-Y and its receptor subtypes in the central nervous system: emphasis on their role in animal models of psychiatric disorders.  In: Neuropeptide -Y and related peptides. Ed. michel MC Springer Verlag Berlin; 2004: pp 101-136
• 34 Rothschild A J, Samson J A, Bessette M P, Carter-Campbell J T. Efficacy of the combination of fluoxetine and perphenazine in the treartment of psychotic depression.  J Clin Psychiat. 1993;  54 338-342
• 35 Schmidt A, Lebel L, Koe B K, Seeger T, Heym J. Sertraline potently displaces (+)-3H-PPP binding to sites in the rat brain.  Eur J Pharmacol. 1989;  165 335-336
• 36 Spiker D G, Weiss J C, Dealy R S. The [pharmacological treatment of delusional depression AMER.  J Psychiat. 1985;  142 430-436
• 37 Stahl S M, Shayegan D. New discoveries in the development of antipsychotics with novel mechanisms of action: beyond the atypical antipsychotics with serotonin dopamine antagonism.  In: Atypical Antipsychotics. Eds. Ellenbroek BA, Cools AR Academic Press NY 2000: pp 215-232
• 38 Su T- P, Weissman A D, Yeh S- Y. Endogenous ligands for sigma opioid receptors in the brain: evidence from binding assays.  Life Sci. 1986;  38 2199-2210
• 39 Su T- P, London E D, Jaffe J H. Steroid binding at sigma receptors suggests a link between endocrine, neurotransmitter and immune systems.  Science. 1988;  240 219-221
• 40 Takebayashi M, Hayashi T, Su T- P. Nerve growth factor-induced neurite prouting in PC12 cells involves sigma-receptors: implications for antidepressants.  J Pharmacol Exp Ther. 2002;  303 1227-1237
• 41 Tam S W, Cook L. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-SKF-10 047 and 3H-haloperidol binding in guines pig brain membranes.  Proc Natl Acad Sci USA. 1984;  81 5618-5621
• 42 Taylor D P, Shukla U A, Wolfe S A, Owen P Q, Pyke R, DeSouza E B. Phase 1 trials of BMY 14 802, a potential antipsychotic with affinity for sigma binding sites.  Schizophrenia Res. 1991;  4 327.u
• 43 Walker J M, Matsumato R R, Bowen W D, Gans D L, Jones K D, Walker F O. Evidence for the role of haloperidol -sensitive sigma opiate receptors in the motor effects of antipsychotic drugs.  Neurology. 1988;  38 961-965
• 44 Walker J M, Bowen W D, Walker F O, Matsumoto R R, de Costa B, Rice K C. Sigma receptors: biology and function.  Pharmacol Revs. 1990;  42 356-401
• 45 Yamamoto H, Yamamoto Y, Sagi N, Klenerova V, Goji K. Sigma ligands indirectly modulate the NMDA receptor ion channel complex on intact neuronal cells via sigma-1 sites.  J Neurosci. 1995;  15 731-736
• 46 Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline verses paroxetine in the treatment of delusional depression.  Am J Psychiat. 1996;  153 1631-1633
• 47 Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study.  J Clin Psychopharmacol. 1998;  18 441-446
• 48 Zhang A Z, Mitchell K N, Cook L, Tam S W. Human endogenous brain ligands for the sigma opioid and phencyclidine receptors.  In: Sigma and phencyclidine - like compounds as molecular probes in biology. Eds. Domino EF, Kameuka JM. NPP Books, Ann Arbor, MI 1988: pp. 335-343
• 49 Zukin R S, Zukin S R. Specific [3H] phencyclidine binding in rat central nervous system.  Proc Natl Acad Sci USA. 1979;  76 5372-5376
• 50 Zukin S R, Zukin R S. Demonstration of [3H] cyclazocine binding to multiple opiate receptor sites.  Mol Pharmacol. 1981;  20 246-254
• 51 Zukin S R, Tempel A, Gardner E L, Zukein R S. Interaction of 3H-(-) SKF 10 047 with brain sigma receptors: characterization and autoradiographic visualization.  J Neurosci. 1986;  46 1032-1041